Literature DB >> 3182962

Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.

T O Pitts1, B H Piraino, R Mitro, T C Chen, G V Segre, A Greenberg, J B Puschett.   

Abstract

It has been postulated that hyperparathyroidism in chronic renal failure results from hypocalcemia, occurring, in part, from phosphate retention and/or deficient 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] synthesis. However, many studies have failed to demonstrate hyperphosphatemia or low 1,25-(OH)2D levels in patients with mild renal failure. We measured creatinine clearance (CCr), fractional excretion of phosphorus (FEP), and serum phosphorus, ionized calcium, and plasma N-terminal PTH, and 1,25-(OH)2D concentrations in 21 normal subjects and 51 patients with renal failure. Patients with mild renal failure (Ccr, greater than 40 mL/min.1.73 m2) had normal mean serum phosphorus and ionized calcium and decreased mean 1,25-(OH)2D levels compared with those in normal subjects. In patients with moderate renal failure (CCr, 20-40), the mean ionized calcium level was normal, plasma PTH levels and FEP were elevated, and the decrement in 1,25-(OH)2D was more pronounced. The mean ionized calcium level was decreased only in the group of patients with severe renal failure (CCr, less than 20). The 1,25-(OH)2D values correlated positively with CCr and negatively with the log of plasma PTH and serum phosphorus concentrations. Log of plasma PTH correlated negatively with CCr and positively with FEP. The ionized calcium concentration correlated very weakly with CCr and the log of the plasma PTH level. These data demonstrate the presence of hyperparathyroidism, normocalcemia, and 1,25-(OH)2D deficiency in renal failure and are consistent with a role for 1,25-(OH)2D in the suppression of parathyroid activity through as yet unidentified mechanisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182962     DOI: 10.1210/jcem-67-5-876

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  42 in total

1.  Timing of onset of CKD-related metabolic complications.

Authors:  Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray
Journal:  J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 10.121

2.  A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.

Authors:  Naveed Haq; Ahmed Chaaban; Nicole Gebran; Imran Khan; Fayez Abbachi; Muhyeddin Hassan; Roos Bernsen; Samra Abouchacra
Journal:  Int Urol Nephrol       Date:  2013-03-26       Impact factor: 2.370

Review 3.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Associations between serum leptin level and bone turnover in kidney transplant recipients.

Authors:  Csaba P Kovesdy; Miklos Z Molnar; Maria E Czira; Anna Rudas; Akos Ujszaszi; Laszlo Rosivall; Miklos Szathmari; Adrian Covic; Andras Keszei; Gabriella Beko; Peter Lakatos; Janos Kosa; Istvan Mucsi
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

5.  Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat.

Authors:  T Naveh-Many; J Silver
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

6.  Disordered FGF23 and mineral metabolism in children with CKD.

Authors:  Anthony A Portale; Myles Wolf; Harald Jüppner; Shari Messinger; Juhi Kumar; Katherine Wesseling-Perry; George J Schwartz; Susan L Furth; Bradley A Warady; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 8.237

7.  Association of serum phosphate with vascular and valvular calcification in moderate CKD.

Authors:  Kathryn L Adeney; David S Siscovick; Joachim H Ix; Stephen L Seliger; Michael G Shlipak; Nancy S Jenny; Bryan R Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

Review 8.  Bone and mineral disorders in pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

9.  The effect of raloxifene treatment in postmenopausal women with CKD.

Authors:  Areef Ishani; Terri Blackwell; Sophie A Jamal; Steven R Cummings; Kristine E Ensrud
Journal:  J Am Soc Nephrol       Date:  2008-04-09       Impact factor: 10.121

Review 10.  Mineral metabolism and bone abnormalities in children with chronic renal failure.

Authors:  Cheryl P Sanchez
Journal:  Rev Endocr Metab Disord       Date:  2008-01-04       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.